U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE			
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT		Docket Number: 395/35	
Application Number 09/510,562	Filing Date February 22, 2000	Examiner D. Guzo	Art Unit 1636
Invention Title METHOD OF SCREENING FOR PROTEIN INHIBITORS AND ACTIVATORS		Inventor(s) Gerard M. HOUSEY	

Address to:

Commissioner for Patents Washington D.C. 20231

SIR:

- 1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 37 C.F.R. §§ 1.97(c) and 1.98 and M.P.E.P. § 609, Applicant hereby brings the attached Opinion to the attention of the Examiner.
- 2. The opinion, which is being appealed, was rendered December 4, 2003 in Bayer AG v. Housey Pharmaceuticals, Inc., and concerns U.S. Patents that issued from applications to which the instant application claims priority under 35 U.S.C. § 120.
- 3. The filing of this Information Disclosure Statement and the enclosed PTO Form No. 1449, shall not be construed as an admission that the information cited is prior art, or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b).
- 4. No item of information contained in this IDS was known to any individual designated in § 1.56(c) for than three months prior to filing of this IDS.
- 5. It is believed that no fees are due in connection with this Information Disclosure Statement. However, should any fees be due, the Commissioner is authorized to charge Deposit Account No. 11-0600 of Kenyon & Kenyon for such fees. A duplicate copy of this communication is enclosed for charging purposes.

Dated: January 8, 2004

Lawrence P. Casson (Reg. No. 46,606)

KENYON & KENYON One Broadway New York, N.Y. 10004 (212) 425-7200 (telephone) (212) 425-5288 (facsimile)

NY01 696497 v 1

Page 1 of 1